71
Participants
Start Date
June 30, 2012
Primary Completion Date
August 31, 2015
Study Completion Date
February 28, 2018
KW-0761
1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
Pralatrexate
30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
gemcitabine plus oxaliplatin
gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
DHAP
dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
Cliniques Universitaires Saint-Luc, Brussels
Memorial Sloan Kettering, New York
Columbia Presbyterian, New York
Weill Cornell Medical College, New York
Montefiore Medical Center, The Bronx
National Cancer Institute, Bethesda
University of Miami / Sylvester Comprehensive Cancer Center, Miami
Northwestern University, Chicago
Washington University School of Medicine, St Louis
Hospital Necker, Paris
Cedars-Sinai Medical Center, Los Angeles
Hackensack University Medical Center, Hackensack
Hospital Universitario Professor Edgard Santos- UFBA, Salvador, Bahia
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo- SP
CHU de Fort de France, Fort de France Cedex
Hospital Nacional Edgardo Rebagliati Martins, Lima
Instituto Oncologico Miraflores, Lima
Guy's Hospital, London
Imperial College, London
Sandwell General Hospital, West Midlands
Lead Sponsor
Kyowa Kirin, Inc.
INDUSTRY